Filed under: Investing
On Tuesday's edition of Market Checkup, Motley Fool health-care analyst David Williamson takes a look at the biggest winners and losers in health care stocks today.
Shares of Cambrex Corporation soared Tuesday, up 15% for the day. News on Monday broke that the company recently passed an FDA manufacturing inspection for its plant in Iowa, and today the stock was upgraded to "overweight" by a company called First Analysis, because of increased confidence that the company would close a large API manufacturing deal with Gilead for its hepatitis C drug Sovaldi. There is also the belief that Gilead would give Cambrex preference for future drug opportunities.
In this segment, David discusses why this deal could be a huge deal for the company, and why, when he started digging into Cambrex, he liked what he saw.
So what's the best way for investors to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Why Cambrex Corporation Soared originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.